Department of Neurosurgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Rev Endocr Metab Disord. 2022 Jun;23(3):647-657. doi: 10.1007/s11154-022-09718-9. Epub 2022 Mar 28.
Differentiation of pituitary neuroendocrine tumor (PitNET) tissue from surrounding normal tissue during surgery is challenging. A number of fluorescent agents is available for visualization of tissue discrepancy, with the potential of improving total tumor resection. This review evaluates the availability, clinical and technical applicability of the various fluorescent agents within the field of pituitary surgery. According to PRISMA guidelines, a systematic review was performed to identify reports describing results of in vivo application of fluorescent agents. In this review, 15 publications were included. Sodium Fluorescein (FNa) was considered in two studies. The first study reported noticeable fluorescence in adenoma tissue, the second demonstrated the strongest fluorescence in non-functioning pituitary adenomas. 5-Aminolevulinic acid (5-ALA) was investigated in three studies. One study compared laser-based optical biopsy system (OBS) with photo-diagnostic filter (PD) and found that the OBS was able to detect all microadenomas, even when MRI was negative. The second study retrospectively analyzed twelve pituitary adenomas and found only one positive for fluorescence. The third investigated fifteen pituitary adenomas of which one displayed vague fluorescence. Indocyanine green (ICG) was researched in four studies with variable results. Second-Window ICG yielded no significant difference between functioning and non-functioning adenomas in one study, while a second study displayed 4 times higher fluorescence in tumor tissue than in normal tissue. In three studies, OTL38 showed potential in non-functioning pituitary adenomas. At present, evidence for fluorescent agents to benefit total resection of PitNETs is lacking. OTL38 can potentially serve as a selective fluorescent agent in non-functioning pituitary adenomas in the near future.
在手术中区分垂体神经内分泌肿瘤(PitNET)组织和周围正常组织具有挑战性。有许多荧光剂可用于显示组织差异,有可能提高肿瘤的全切除率。本综述评估了在垂体手术领域中各种荧光剂的可用性、临床和技术适用性。
根据 PRISMA 指南,进行了系统评价,以确定描述荧光剂体内应用结果的报告。在本综述中,纳入了 15 篇文献。有两项研究考虑了荧光素钠(FNa)。第一项研究报告腺瘤组织有明显荧光,第二项研究表明无功能垂体腺瘤的荧光最强。有三项研究调查了 5-氨基酮戊酸(5-ALA)。一项研究比较了基于激光的光学活检系统(OBS)与光诊断滤光片(PD),发现 OBS 能够检测到所有微腺瘤,即使 MRI 结果为阴性。第二项研究回顾性分析了 12 例垂体腺瘤,仅发现 1 例有荧光阳性。第三项研究调查了 15 例垂体腺瘤,其中 1 例显示出模糊荧光。有四项研究调查了吲哚菁绿(ICG),结果各不相同。一项研究中,第二代 ICG 在功能性和无功能性腺瘤之间没有显著差异,而另一项研究显示肿瘤组织的荧光强度比正常组织高 4 倍。在三项研究中,OTL38 在无功能垂体腺瘤中显示出潜力。
目前,缺乏荧光剂有益于 PitNET 全切除的证据。在不久的将来,OTL38 可能成为无功能垂体腺瘤的一种有选择性的荧光剂。